Abeona Therapeutics Inc vs Nerdwallet Inc — how do they compare? Abeona Therapeutics Inc trades at $7.34 (market cap $421.19M), while Nerdwallet Inc trades at $9.43 (market cap $625.17M). The key difference: Nerdwallet Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | NRDS | |
|---|---|---|
Market Cap | $421.19M | $625.17M |
Sector | Health | Financials |
52-Week High | $7.45 | $15.93 |
52-Week Low | $4.17 | $7.58 |
Enterprise Value | $276.10M | $539.47M |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
NRDS trades at $9.76, down 0.41% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue of $197 million, up 6% year-over-year, though EPS missed estimates. Valuation ratios appear attractive with a P/E of 10.87 and P/S of 0.81, while profitability metrics like an 18.16% ROE and 93.5% gross margin remain strong. Recent news highlights analyst optimism for a 27.9% upside potential.
The outlook is positive due to solid fundamentals and growth in personal loans and deposit accounts, offsetting SEO pressures. Risks include execution in shifting business models and competitive threats. With 66.7% of analysts rating it Buy and a consensus bullish stance, the stock presents a growth opportunity amid manageable risks.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →